EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas

Sunita M C De Sousa iD, Ann McCormack iD, Andreas Orsmond, Angeline Shen, Christopher J Yates, Roderick Clifton-Bligh iD, Stephen Santoreneos, James King, Jinghua Feng, John Toubia, David J Torpy, Hamish S Scott

The Journal of Clinical Endocrinology & Metabolism · 2024

DOI: 10.1210/clinem/dgae268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2024. Verfasst von Sunita M C De Sousa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine & Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Checkpoint Kinase 2, Pituitary Neoplasms, Germ-Line Mutation, Adenoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Royal Adelaide Hospital, Royal Australasian College of Physicians, Endocrine Society of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

CHEK2 is a cell cycle checkpoint regulator gene with a long-established role as a clinically relevant, moderate risk breast cancer predisposition gene, with greater risk ascribed to truncating variants than missense variants.

Objective

To assess the rate and pathogenicity of CHEK2 variants amongst individuals with pituitary adenomas (PAs).

Methods

We assessed 165 individuals with PAs for CHEK2 variants. The study population comprised a primary cohort of 29 individuals who underwent germline and tumor whole-exome sequencing, and a second, independent cohort of 136 individuals who had a targeted next-generation sequencing panel performed on both germline and tumor DNA (n = 52) or germline DNA alone (n = 84).

Results

We identified rare, coding, nonsynonymous germline CHEK2 variants amongst 3 of 29 (10.3%) patients in our primary cohort, and in 5 of 165 (3.0%) patients overall, with affected patients having a range of PA types (prolactinoma, thyrotropinoma, somatotropinoma, and nonfunctioning PA). No somatic variants were identified. Two variants were definitive null variants (c.1100delC, c.444 + 1G > A), classified as pathogenic. Two variants were missense variants (p.Asn186His, p.Thr476Met), classified as likely pathogenic. Even when considering the null variants only, the rate of CHEK2 variants was higher in our cohort compared to national control data (1.8% vs 0.5%; P = .049).

Conclusion

This is the first study to suggest a role for the breast cancer predisposition gene, CHEK2, in pituitary tumorigenesis, with pathogenic/likely pathogenic variants found in 3% of patients with PAs. As PAs are relatively common and typically lack classic autosomal dominant family histories, risk alleles—such as these variants found in CHEK2—might be a significant contributor to PA risk in the general population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Checkpoint Kinase 2Pituitary NeoplasmsGerm-Line MutationAdenomaGenetic Predisposition to DiseaseHumansFemaleMaleAdultMiddle AgedAgedCohort StudiesPrevalenceExome SequencingYoung AdultMutation, Missense

Stichwörter der Autor:innen

cell cycle checkpoint kinase 2 (CHEK2)pituitary adenomaswhole-exome sequencing

Substanzen

Checkpoint Kinase 2CHEK2 protein, human

Autor:innen und Institutionen

  • Endocrine & Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
  • South Australian Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
  • Adelaide Medical School, University of Adelaide, Adelaide, SA 5000, Australia.
  • Department of Endocrinology, St Vincent's Hospital, Sydney, NSW 2000, Australia.
  • Hormones and Cancer Group, Garvan Institute of Medical Research, Sydney, NSW 2000, Australia.
  • St Vincent's Clinical School, University of New South Wales, Sydney, NSW 2000, Australia.

ORCID-Profile: Sunita M C De Sousa, Ann McCormack, Roderick Clifton-Bligh

Förderung

  • Royal Adelaide Hospital
  • Royal Australasian College of Physicians
  • Endocrine Society of Australia

Zitieren

APA

De Sousa, S. M. C., McCormack, A., Orsmond, A., Shen, A., Yates, C. J., Clifton-Bligh, R., Santoreneos, S., King, J., Feng, J., Toubia, J., Torpy, D. J., & Scott, H. S. (2024). Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae268

Vancouver

De Sousa SMC, McCormack A, Orsmond A, Shen A, Yates CJ, Clifton-Bligh R, et al. Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas. The Journal of Clinical Endocrinology & Metabolism. 2024. doi:10.1210/clinem/dgae268

BibTeX
@article{DeSousa2024,
  author = {De Sousa, Sunita M C and McCormack, Ann and Orsmond, Andreas and Shen, Angeline and Yates, Christopher J and Clifton-Bligh, Roderick and Santoreneos, Stephen and King, James and Feng, Jinghua and Toubia, John and Torpy, David J and Scott, Hamish S},
  title = {Increased Prevalence of Germline Pathogenic CHEK2 Variants in Individuals With Pituitary Adenomas},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  doi = {10.1210/clinem/dgae268}
}
Kostenlos starten →